Company profile
INTENSITY THERAPEUTICS, INC.
NASDAQ:INTSBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03058289 | phase1_2 | completed | 2017-02-09 | 2023-02-22 | Intensity Therapeutics, Inc. | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 |
| NCT06263231 | phase3 | recruiting | 2024-06-28 | 2027-12-01 | Intensity Therapeutics, Inc. | A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) |
FDA applications (0)
No records yet.